Lung cancer remains the leading cause of cancer-related death worldwide, largely due to late-stage diagnosis. Although low-dose computed tomography (LDCT) screening can reduce mortality, it is limited by high false-positive rates, radiation exposure, and low adherence. Thus, there is an urgent need for precise, accessi...
Peter Hjorth-Hansen, C. Jacobsen, L. Nederby et al.· Journal of Molecular Diagnos...· 0 citations
Background: Lung cancer is a heterogeneous disease with unpredictable trajectories. Risk stratification in lung cancer remains imprecise within tumor-node-metastasis (TNM) stages. Objectives: This work aims to evaluate whether methylated circulating tumor DNA (ctDNA) can improve prognostication at the time of diagnosis...
Peter Hjorth-Hansen, L. Nederby, C. Jacobsen et al.· Therapeutic Advances in Medi...· 0 citations
We assessed the feasibility of a multi-reader, multi-case (MRMC) observer-performance design to evaluate the simulated decision impact of a radiomics-based computer-assisted diagnostic tool (CADx) and a methylated circulating tumour DNA (ctDNA) assay in lung cancer work-up. Patients referred to a Danish fast-track lung...
Peter Hjorth-Hansen, S. Wen, T. Hansen et al.· Scientific Reports· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.